Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

COMy 2022 | Highlights from COMy

Arnon Nagler • 13 May 2022
COMy 2022
Multiple Myeloma Antibodies CAR-T

Arnon Nagler, MD, Chaim Sheba Medical Center, Tel Aviv, Israel, briefly discusses the excitement around the COMy 2022 meeting, and highlights some of the topics being presented. Prof. Nagler also discusses how the myeloma treatment landscape is advancing with the introduction of novel immunotherapies. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.

More from Arnon Nagler

Transplanting patients with advanced AML 3:07
Transplanting patients with advanced AML
Arnon Nagler • 30 Mar 2025
Bone marrow versus mobilized peripheral blood grafts for haploidentical transplant in secondary AML 1:42
Bone marrow versus mobilized peripheral blood grafts for haploidentical transplant in secondary AML
Arnon Nagler • 30 Mar 2025
Is there a preferable donor for alloSCT in secondary AML in first complete remission? 2:23
Is there a preferable donor for alloSCT in secondary AML in first complete remission?
Arnon Nagler • 30 Mar 2025
Advancements in a point-of-care approach to CAR T-cell manufacturing & ongoing programs 3:22
Advancements in a point-of-care approach to CAR T-cell manufacturing & ongoing programs
Arnon Nagler • 30 Mar 2025

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals